Abstract Number: 1809 • ACR Convergence 2022
Impact of Colchicine Prophylaxis on Cardiovascular Outcome Among Gout Patients: A Secondary Analysis of CARES Trial
Background/Purpose: Low-dose colchicine has been demonstrated to reduce cardiovascular (CV) events in two recent large cardiovascular trials. Gout patients, for whom colchicine is a highly relevant…Abstract Number: 1810 • ACR Convergence 2022
Frequency and Patterns of Opioid Use in the Management of Gout: A Population-Based Study
Background/Purpose: Treatment guidelines for management of gout do not recommend opioids. We evaluated the frequency of opioid prescriptions in those with gout compared with the…Abstract Number: 1811 • ACR Convergence 2022
Urate Lowering Therapy Initiation in Hospitalized Patients with Acute Gout Flares
Background/Purpose: Identifying patients with gout who would benefit from urate lowering therapies (ULT) is of utmost importance to help limit both pain and functional pain.…Abstract Number: 1812 • ACR Convergence 2022
Impact of Misclassification on the US Prevalence of Gout: Bayesian Sensitivity Analysis of the National Health & Nutrition Examination Survey (NHANES)
Background/Purpose: Gout is considered the most common inflammatory arthritis in the US with an estimated prevalence of 3.9% based on the National Health and Nutrition…Abstract Number: 1813 • ACR Convergence 2022
Patient-Reported Outcomes in CPPD Compared to Gout and Osteoarthritis
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease prevalence is similar to gout and osteoarthritis (OA), yet CPPD outcomes research greatly lags behind these other forms of…Abstract Number: 1814 • ACR Convergence 2022
Pegloticase for Uncontrolled Gout in Patients with History of Kidney Transplant: Pharmacokinetics and Immunogenicity in the PROTECT Clinical Trial
Background/Purpose: Immunomodulator co-therapy with pegloticase has been shown to reduce immunogenicity (anti-drug antibody [ADA] development), which markedly improves response rates with pegloticase while reducing risk…Abstract Number: 1815 • ACR Convergence 2022
Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease
Background/Purpose: Patients with gout are more likely than those without to have traditional risk factors for cardiovascular (CV) disease. Furthermore, the chronic, low-level inflammation experienced…Abstract Number: 1816 • ACR Convergence 2022
Assessing Urate Deposition and Inflammation in the Vasculature of Gout Patients Using Dual Energy Computed Tomography and Positron Emission Tomography Pre and Post Pegloticase- a Pilot Study
Background/Purpose: Gout is the most common inflammatory arthritis, caused by hyperuricemia and subsequent deposition of aggregated monosodium urate (MSU) crystals in both articular and extra-articular…Abstract Number: 1818 • ACR Convergence 2022
Hepatic Steatosis and Fibrosis in Patients with Gout Detected by Elastography
Background/Purpose: Gout is associated with non-alcoholic fatty liver disease (NAFLD), but neither the frequency nor severity of NAFLD in gout is well described. Elastography is…Abstract Number: 1820 • ACR Convergence 2022
Targeted Plasma Lipidomics Distinguishes Patients with Gout and Hyperuricemia from Controls
Background/Purpose: Gout is the most common type of inflammatory arthritis, characterised by chronic deposition of uric acid crystals in the joints, affecting approx. 1-2% of…Abstract Number: 1821 • ACR Convergence 2022
Colchicine and Other Gout Medications and the Risk of COVID-19 Infection, Hospitalization, and Subsequent Outcomes in People with Gout
Background/Purpose: To examine whether the use of colchicine and other gout medications is associated with the risk of COVID-19 infection, hospitalization, and subsequent outcomes in…Abstract Number: 1822 • ACR Convergence 2022
A Double-Blind, Placebo-Controlled, Ascending Dose Phase 2a Study of ABP-671, a Novel, Potent and Selective URAT1 Inhibitor, in Patients with Gout or Hyperuricemia
Background/Purpose: ABP-671, a novel selective and potent URAT1 inhibitor reduces reabsorption of uric acid (UA) at the renal proximal tubule, and significantly decreases serum uric…Abstract Number: 1823 • ACR Convergence 2022
Unsupervised Cluster Analysis of Clinical and Ultrasound Features Reveals Unique Gout Subtypes: Results from the Egyptian College of Rheumatology (ECR)
Background/Purpose: Gout comprises a heterogeneous group of disorders characterized by inflammatory arthritis associated with comorbidities leading to impaired quality of life, and an extensive burden…Abstract Number: 1824 • ACR Convergence 2022
eGFR Changes in Uncontrolled Gout Patients Undergoing Pegloticase + Methotrexate Co-therapy
Background/Purpose: Chronic kidney disease (CKD) has been associated with gout1 and CKD worsening has been associated with hyperuricemia.2,3 Pegloticase can lower serum uric acid (sUA)…Abstract Number: 1827 • ACR Convergence 2022
The Updated Cardiovascular Risk Tool SCORE2 Provides No Advantage in Identifying Patients with Gout and Carotid Atheroma Plaques
Background/Purpose: Standard cardiovascular (CV) risk assessment tool (SCORE, Framingham Heart Study) performed inaccurately in patients with gout and carotid atheroma plaques (thus, at high CV…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »